44.24
0.89%
+0.39
After Hours:
44.24
Ultragenyx Pharmaceutical Inc. stock is currently priced at $44.24, with a 24-hour trading volume of 447.45K.
It has seen a +0.89% increased in the last 24 hours and a -2.68% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $43.52 pivot point. If it approaches the $44.32 resistance level, significant changes may occur.
Previous Close:
$43.85
Open:
$44.16
24h Volume:
447.45K
Market Cap:
$3.64B
Revenue:
$434.25M
Net Income/Loss:
$-606.64M
P/E Ratio:
-4.932
EPS:
-8.97
Net Cash Flow:
$-521.57M
1W Performance:
+4.41%
1M Performance:
-2.68%
6M Performance:
+28.19%
1Y Performance:
+4.51%
Ultragenyx Pharmaceutical Inc. Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc.
Sector
Industry
Phone
415-483-8800
Address
60 Leveroni Court, Novato, CA
Ultragenyx Pharmaceutical Inc. Stock (RARE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Jun-14-23 | Resumed | Credit Suisse | Outperform |
Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
Jan-18-23 | Resumed | Canaccord Genuity | Buy |
Dec-30-22 | Resumed | H.C. Wainwright | Buy |
Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-30-21 | Initiated | H.C. Wainwright | Buy |
Aug-19-21 | Initiated | UBS | Sell |
Jul-15-21 | Initiated | Guggenheim | Neutral |
Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
Jun-04-21 | Resumed | Robert W. Baird | Neutral |
May-06-21 | Upgrade | Citigroup | Neutral → Buy |
May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
Apr-26-21 | Resumed | Credit Suisse | Neutral |
Mar-02-21 | Resumed | Stifel | Buy |
Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
Nov-24-20 | Resumed | Evercore ISI | In-line |
Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
Aug-02-19 | Resumed | Wedbush | Outperform |
Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Feb-22-19 | Resumed | Raymond James | Outperform |
Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
May-10-18 | Initiated | Goldman | Neutral |
Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
Mar-22-18 | Resumed | Piper Jaffray | Overweight |
Feb-21-18 | Reiterated | Stifel | Buy |
Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
Jan-18-18 | Initiated | Credit Suisse | Outperform |
Dec-05-17 | Reiterated | Barclays | Equal Weight |
Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc. Stock (RARE) Latest News
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire Inc.
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Zacks Investment Research
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Ultragenyx Pharmaceutical Inc. Stock (RARE) Financials Data
Ultragenyx Pharmaceutical Inc. (RARE) Revenue 2024
RARE reported a revenue (TTM) of $434.25 million for the quarter ending December 31, 2023, a +19.52% rise year-over-year.
Ultragenyx Pharmaceutical Inc. (RARE) Net Income 2024
RARE net income (TTM) was -$606.64 million for the quarter ending December 31, 2023, a +14.25% increase year-over-year.
Ultragenyx Pharmaceutical Inc. (RARE) Cash Flow 2024
RARE recorded a free cash flow (TTM) of -$521.57 million for the quarter ending December 31, 2023, a +0.95% increase year-over-year.
Ultragenyx Pharmaceutical Inc. (RARE) Earnings per Share 2024
RARE earnings per share (TTM) was -$8.33 for the quarter ending December 31, 2023, a +17.61% growth year-over-year.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. It has a collaboration agreement with Rentschler Fill Solutions GmbH. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Cap:
|
Volume (24h):